Immunotherapy, a revolutionary approach to cancer treatment, has garnered significant attention in the medical community. This technique leverages the body's immune system to combat cancerous cells, offering a promising alternative to traditional treatments. This article aims to elucidate the essential aspects of immunotherapy for physicians.
Immunotherapy, also known as biotherapy, involves stimulating or restoring the immune system's ability to fight infections and diseases. It can be classified into two types: active and passive. Active immunotherapy boosts the immune system to attack cancer cells, while passive immunotherapy involves the use of immune system components, such as monoclonal antibodies, to target cancer cells.
Immunotherapy encompasses various modalities, including monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapy. Monoclonal antibodies are designed to bind to specific targets on cancer cells. Immune checkpoint inhibitors help the immune system recognize and attack cancer cells. Cancer vaccines, like the Sipuleucel-T for prostate cancer, stimulate the immune system to attack specific types of cancer cells. Adoptive cell therapy involves enhancing the natural cancer-fighting ability of the patient's T cells.
Immunotherapy offers several benefits, including precision targeting of cancer cells, reduced side effects, and potential for long-term cancer control. However, it also carries risks, such as immune-related adverse events (irAEs) like inflammation and autoimmune reactions. Physicians should carefully consider these factors when deciding on a treatment plan.
Immunotherapy represents a significant stride in cancer treatment, offering a novel approach that leverages the body's own defenses. As research progresses, it is hoped that this treatment modality will become increasingly effective and widely accessible. Physicians must stay abreast of these developments to provide the best care for their patients.
1.
The risk of ovarian cancer is not increased by salpingectomy, according to JAMA.
2.
What is a "cancer vaccine" and is it the same as a COVID vaccine?
3.
Predicting adult mortality from oral cancer using a machine learning approach.
4.
DNA's hidden shape reveals target to reverse ovarian cancer chemoresistance
5.
Studies show that treatment for non-Hodgkin's lymphoma is also focused on the lymphoma.
1.
Federated Hematology Data Networks for Collaborative Research Without Centralized Patient-Level Data
2.
Liquid Biopsies Unveiling the Future of Precision Cancer Management by 2025
3.
Understanding the Importance of CA125: A Comprehensive Guide
4.
Cerebrospinal Fluid Metabolite Biomarkers in Central Nervous System Tumor Monitoring: A New Frontier
5.
HSC Failure in Fanconi Anemia: Mechanisms, Models, and Emerging Therapeutic Pathways
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
2.
Navigating the Complexities of Ph Negative ALL - Part V
3.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
4.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
5.
Current Scenario of Cancer- Q&A Session to Close the Gap
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation